A short social post frames the semaglutide molecule as the start of a bigger business story for drugmakers, with a note that it is not medical advice.
Recap by typeshit. Post by @socho.abhi on Instagram.
Novo also reported 25% average weight loss in women on CagriSema in a post-hoc trial analysis, while BMO flagged Ozempic losing US share.
Dr. Nadolsky responds to a clip from comedian @stavvybaby2 about GLP-1s, adding a doctor's view to the joke.
He calls GLP-1 drugs useful before surgery or after regain, but says surgery stays the main option for people who need large, lasting weight loss.
An anonymous poster says people put their dramatic weight loss down to their mother's death, when it was really Ozempic they wanted to keep quiet.
Marchione makes the case for pairing GLP-1s with drugs that target amylin, the hormone released after meals that signals fullness to the brain.
Portela calls out people taking advice from TikTok comments to self-inject powders labeled not for human consumption, with melanotan as the example.
Loading…